Is centralization of ovarian cancer care warranted?. A cost-effectiveness analysis

Gynecologic Oncology

Volumn 113, Issue 1, 2009, Pages 68-74

  Greving, Jacoba P ^a   Vernooij, Flora ^a   Heintz, A Peter M ^a   van der Graaf, Yolanda ^a   Buskens, Erik ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Centralized care; Cost effectiveness analysis; Gynecologic oncologist; Hospital setting; Ovarian cancer; Quality adjusted life years

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; GENERAL HOSPITAL; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NETHERLANDS; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE;

CANCER CARE FACILITIES; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HOSPITALS, GENERAL; HUMANS; NEOPLASM STAGING; NETHERLANDS; ONCOLOGY SERVICE, HOSPITAL; OVARIAN NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 62549146586     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.12.008     Document Type: Article

References (22)

1. Junor E.J., Hole D.J., McNulty L., Mason M., and Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br. J. Obstet. Gynaecol. 106 (1999) 1130-1136
2. Grossi M., Quinn M.A., Thursfield V.J., Francis P.A., Rome R.M., Planner R.S., et al. Ovarian cancer: patterns of care in Victoria during 1993-1995. Med. J. Aust. 177 (2002) 11-16
3. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 98 (2006) 172-180
4. Engelen M.J., Kos H.E., Willemse P.H., Aalders J.G., de Vries E.G., Schaapveld M., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106 (2006) 589-598
5. Vernooij F., Heintz P., Witteveen E., and van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol. Oncol. 105 (2007) 801-812
6. Vernooij F, Heintz A, Coebergh JW, Massuger LF, Witteveen P, van der Graaf Y. Impact of specialty and volume of care provider on surgical results and on survival of ovarian cancer patients. Gynecol Oncol in press.
7. Heintz A.P., Hacker N.F., Berek J.S., Rose T.P., Munoz A.K., and Lagasse L.D. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet. Gynecol. 67 (1986) 783-788
8. Aletti G.D., Gostout B.S., Podratz K.C., and Cliby W.A. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol. Oncol. 100 (2006) 33-37
9. Bristow R.E., Santillan A., Diaz-Montes T.P., Gardner G.J., Giuntoli R.L., Meisner B.C., et al. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 109 (2007) 1513-1522
10. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: a practical guide. Med. Decis. Mak. 13 (1993) 322-338
11. Epithelial ovarian tumors. In: van de Berg W., Eliel M., and Battermann J. (Eds). Oncology book of the Dutch Association of Comprehensive Cancer Centers: guidelines for diagnosis and treatment of cancer for medical specialists and general practitioners (1996), Dutch Association of Comprehensive Cancer Centers, Utrecht
12. Oostenbrink J.B., Bouwmans C.A., Koopmanschap M.A., and Rutten F.F. Instructions for cost sssessment, methods and directive of prices for economic evaluation in health care (2004), Health Care Insurance Board, Amstelveen
13. Pharmacotherapeutic compass 2006 (http://www.fk.cvz.nl).
14. Reported healthiness and lifestyle of the Dutch population by age and sex (http://statline.cbs.nl).
15. Grann V.R., Panageas K.S., Whang W., Antman K.H., and Neugut A.I. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J. Clin. Oncol. 16 (1998) 979-985
16. Grann V.R., Jacobson J.S., Sundararajan V., Albert S.M., Troxel A.B., and Neugut A.I. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J. Sci. Am. 5 (1999) 283-292
17. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B., and Stoddart G.L. Methods for economic evaluation of health care programmes. 3rd edition (2005), Oxford University Press, Oxford
18. Ovarian cancer practice guideline from the Dutch Comprehensive Cancer Center (http://www.oncoline.nl).
19. Ghezzi F., Cromi A., Uccella S., Bergamini V., Tomera S., Franchi M., et al. Laparoscopy versus laparatomy for the surgical management of apparent early stage ovarian cancer. Gynecol. Oncol. 105 (2007) 409-413
20. Park J.Y., Kim D.Y., Suh D.S., Kim J.H., Kim Y.M., Kim Y.T., et al. Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann. Surg. Oncol. 15 (2008) 2012-2019
21. Tingulstad S., Hagen B., Skjeldestad F.E., Onsrud M., Kiserud T., Halvorsen T., et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br. J. Obstet. Gyneacol. 103 (1996) 826-831
22. Dutch working population by age and sex (http://statline.cbs.nl).